Singh BNControlling cardiac arrhythmia: An overview in a historical perspective. Am J Cardiol80:4G, 1997
2.
Zipes DPAn overview of arrhythmias and antiarrhythmic approaches. J Cardiovasc Electrophysiol10:267, 1999
3.
Zipes DPAtrial fibrillation: From cell to bedside. J Cardiovasc Electrophysiol8:927, 1997
4.
Singh BN, Mody FV, Lopez B., et al. Antiarrhythmic agents for atrial fibrillation: Focus on prolonging atrial repolarization. Am J Cardiol84:161R, 1999
5.
Grogan M., Smith HC, Gersh BL, et al. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol69:1570, 1992
6.
Manning W., Leeman DE, Gotch PJ, et al. Pulse I Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation. J Am Coll Cardiol13:617, 1989
7.
Hart RG, Halperin JLAtrial fibrillation and thromboembolism: A decade of progress in stroke prevention . Ann Intern Med131:688, 1999
8.
Wijffels MC, Kirchhof CJ, Dorland R., et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation92:1954, 1995
9.
Le Huezy J-Y. , Boutjdir M., Gagey S., et al. Cellular aspects of atrial vulnerability . In Attuel P, Coumel P, Janse MJ (eds). The Atrium in Health and Disease. Futura Publishing Co. Inc., Mt. Kisco, NY, pp. 81-95, 1989
10.
Freedberg AS , Papp JG, Vaughan Williams EM. The effects of altered thyroid state on atrial intracellular potentials. J Physiol207:357, 1970
11.
Singh BNCurrent antiarrhythmic drugs: An overview of mechanisms of action and potential clinical utility. J Cardiovasc Electrophysiol10:283, 1999
12.
Wang Z., Pelletier LC, Talajic M., et al. Effects of flecainide and quinidine on human atrial potentials: Role of rate dependence and comparison with guinea pig, rabbit and dog tissues . Circulation82:274, 1990
13.
Valdeberrano M., Singh BNElectrophysiologic and antiarrhythmic effects of propafenone: Focus on atrial fibrillation. J Cardiovasc Pharmacol Therapeut4:183, 1999
14.
Roy D., Talajic M., Dorian P., et al., for Canadian Trial of Atrial Fibrillation Investigators.Amidarone to prevent recurrence of atrial fibrillation. N Engl J Med342:919, 2000
15.
Singh BNSotalol: Current status and expanding indications. J Cardiovasc Pharmacol Therapeut4(1):49, 1999
16.
Reimold SC, Cantillon CO, Friedman PL, et al. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol71:558, 1993
17.
Belinda F., Abuzz RP, Nicola L., et al. Propafenone and sotalol in the prevention of paroxysmal atrial fibrillation: Long term safety and efficacy study. Curr Ther Res56:1154, 1995
18.
Juul-Moller S., Edvardsson N., Ahlberg NRSotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation82:1932, 1990
19.
Benditt DG, Williams JH, Jin J., et al., for the dl-Sotalol Atrial Fibrillation/Flutter Study Group.Maintenance of sinus rhythm with oral dl-sotalol therapy in patients with symptomatic atrial fibrillation and flutter: A dose-response study. Am J Cardiol84:270, 1999
20.
Torp-Pedersaen C., Moeller M., Bloch-Thomsen P., et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med341:857, 1999
21.
Singh BNAntiarrhythmic drugs: A re-orientation in light of recent developments in the control of disorders of rhythm. Am J Cardiol81:3D, 1998
22.
Singh BNAntiarrhythmic actions of amiodarone: A profile of a paradoxical agent. Am J Cardiol78:41, 1996
23.
Kodama I., Kamiya K., Toyama J.Cellular electropharmacology of amiodarone. Cardiovasc Res35:13, 1997
24.
Nattel S., Singh BNEvolution, mechanisms, and classification of antiarrhythmic drugs: Focus on class III actions. Am J Cardiol84:11R, 1999
25.
Hohnloser S. , Klingenheben T., Singh BNAmiodarone-associated proarrhythmic effects: A review with special reference to torsades de pointes tachycardia. Ann Intern Med121:529, 1994
26.
Connolly SJMeta-analysis of antiarrhythmic drug trials . Am J Cardiol84:94R, 1999
